Afamelanotide (Scenesse, Clinuvel Pharmaceuticals) is a linear MC1R selective tridecapeptide, approved by the FDA on October 8, 2019, and by the EMA on December 22, 2014, exclusively for the treatment of erythropoietic protoporphyria (EPP) in adults
There is also the practical question of drinking while on a GLP-1 or GIP medication, which we cover in our article on whether you can drink alcohol on GLP-1
Is there detailed information on its mechanism and performance
To learn more, check out the recording of our webinar, GLP-1 Spotlight: Navigating Coverage, Costs, and Clinical Outcomes.
It supports the look of tone uniformity and smoother texture while maintaining comfort, so the complexion stays consistent: less visibly uneven, more controlled, and naturally luminous in real light